Open access
Oct 2026
Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience
The addition of maintenance chemotherapy with low‐dose cyclophosphamide and vinorelbine has improved survival outcomes for patients with high‐risk disease, but the potential SMN risk from increased cumulative alkylating agent exposure remains unclear.
G. Bisogno, A. Ferrari, Raquel Dávila Fajardo et al.
· Cancer · 0 citations